-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Gilead Sciences's Income Statement
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$27.31 B | $27.28 B | $27.12 B | $28.75 B | $29.44 B |
| Cost of Revenue |
|
$6.60 B | $5.66 B | $6.50 B | $6.25 B | $3.92 B |
| Gross Profit |
|
$20.70 B | $21.62 B | $20.62 B | $22.50 B | $25.52 B |
| Research & Development |
|
$4.60 B | $4.98 B | $5.72 B | $5.91 B | $5.69 B |
| Selling,General & Administrative |
|
$5.25 B | $5.67 B | $6.09 B | $6.09 B | $5.71 B |
| Operating Expense |
|
$10.79 B | $14.29 B | $13.01 B | $20.84 B | $13.71 B |
| Operating Income |
|
$9.92 B | $7.33 B | $7.61 B | $1.66 B | $11.82 B |
| Net Income |
|
$6.23 B | $4.59 B | $5.67 B | $480.00 M | $8.51 B |
Gilead Sciences's Assets vs Liabilities & Equity
Gilead Sciences's Balance Sheet
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$6.52 B | $6.39 B | $7.26 B | $11.57 B | $10.61 B |
| Inventories |
|
$1.62 B | $1.51 B | $1.79 B | $1.71 B | $4.37 B |
| Total Current Assets |
|
$14.77 B | $14.44 B | $16.09 B | $19.17 B | $19.89 B |
| Property,Plant and Equipment |
|
$5.12 B | $5.48 B | $5.32 B | $5.41 B | $5.61 B |
| Goodwill |
|
$8.33 B | $8.31 B | $8.31 B | $8.31 B | $8.31 B |
| Total Assets |
|
$67.95 B | $63.17 B | $62.13 B | $59.00 B | $59.02 B |
| Total Liabilities |
|
$46.89 B | $41.96 B | $39.38 B | $39.75 B | $36.41 B |
| Retained Earnings |
|
$16.32 B | $15.69 B | $16.30 B | $11.50 B | - |
| Total Shareholder Equity |
|
$21.07 B | $21.24 B | $22.83 B | $19.33 B | $22.62 B |
| Common Stock |
|
$1.00 M | $1.00 M | $1.00 M | $1.00 M | - |
Gilead Sciences's Cash flow
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$2.05 B | $2.10 B | $2.69 B | $2.77 B | - |
| Dividends Payout |
|
-$3.61 B | -$3.71 B | -$3.81 B | -$3.92 B | - |
| Capital Expenditures (Capex) |
|
-$579.00 M | -$728.00 M | -$585.00 M | -$523.00 M | - |
| Free Cash Flow (FCF) |
|
$10.81 B | $8.34 B | $7.42 B | $10.31 B | $10.02 B |
Gilead Sciences's Profitability
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$20.70 B | $21.62 B | $20.62 B | $22.50 B | $25.52 B |
| Gross Profit Margin (%) |
|
75.82% | 79.26% | 76.04% | 78.26% | 86.69% |
| Operating Income |
|
$9.92 B | $7.33 B | $7.61 B | $1.66 B | $11.82 B |
| Operating Income Margin (%) |
|
36.32% | 26.87% | 28.05% | 5.78% | 40.14% |
| Net Income |
|
$6.23 B | $4.59 B | $5.67 B | $480.00 M | $8.51 B |
| Net Income Margin (%) |
|
22.80% | 16.83% | 20.89% | 1.67% | 28.90% |
| EBITDA |
|
$11.33 B | $8.85 B | $10.50 B | $4.43 B | $10.82 B |
| EBITDA Margin (%) |
|
41.49% | 32.45% | 38.71% | 15.42% | 36.75% |
Gilead Sciences's Ratios
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
29.55% | 21.62% | 24.81% | 2.48% | - |
| Return on Assets (ROA) |
|
9.16% | 7.27% | 9.12% | 0.81% | - |
| Debt to Equity |
|
126.70% | 118.79% | 109.43% | 138.18% | 108.73% |
| Debt to total asset |
|
39.29% | 39.94% | 40.22% | 45.28% | 41.67% |
| Enterprise value to revenue |
|
4.12 | 4.68 | 4.43 | 4.59 | 0.00 |
| Enterprise value to EBITDA |
|
9.94 | 14.41 | 11.43 | 29.75 | 0.00 |
| Enterprise value |
|
$112.56 B | $127.56 B | $120.00 B | $131.91 B | - |
| Tax Rate (%) |
|
25.09% | 21.47% | 18.18% | 30.58% | 13.13% |
Frequently Asked Questions
